<DOC>
	<DOCNO>NCT01739829</DOCNO>
	<brief_summary>The purpose study establish safety efficacy xenotransplantation DIABECELL® patient establish type 1 diabetes mellitus</brief_summary>
	<brief_title>Open-label Investigation Safety Effectiveness DIABECELL® Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Intraperitoneal islet transplantation potential ameliorate type 1 diabetes mellitus avert long-term consequence chronic diabetes achieve conventional insulin treatment . As donor human islet available sufficient number , porcine islet best alternative source recognise physiologically compatible xenogeneic insulin-producing cell . Although use pig-derived cell raise risk xenotic infection , minimise obtain cell designate pathogen-free ( DPF ) animal breed isolation monitor free specify pathogen . The worldwide experience date 200 patient receive transplant pig tissue demonstrate evidence transmit xenotic infection . As animal-derived tissue protect immune rejection transplant human , transplant usually accompany immunosuppressive therapy . However , porcine islet preferably transplant without use immunosuppressive drug cause significant morbidity . To protect immune rejection , islet encapsulate alginate microcapsules permit inward passage nutrient glucose outward passage insulin . Alginate-encapsulated porcine islet transplant without immunosuppressive drug survive rejection many month animal study , retrieve diabetic patient 9.5 year intraperitoneal transplantation show contain viable islet stain positive insulin . DIABECELL® comprise neonatal porcine islet encapsulate alginate microcapsules . DIABECELL® safely transplant healthy diabetic mouse , rat , rabbit , dog non-human primate . Following DIABECELL® transplant , requirement daily insulin significantly reduce diabetic rat non-human primate . The optimal dose frequency transplantation current DIABECELL® preparation treatment type 1 diabetes human determine clinical trial . The intention phase I/IIa clinical trial obtain least 52 week safety preliminary efficacy data type 1 diabetic patient follow transplantation two low effective dos DIABECELL® peritoneal cavity .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Adults ( male female ) age range 18 65 year Diagnosis type 1 diabetes mellitus ( minimum duration 5 year ) accordance American Diabetes Association 's criterion . Patients treat continuously insulin since diagnosis ( Expert Committee Diagnosis Classification Diabetes Mellitus 2002 ) Patients establish brittle type I diabetes mellitus welldocumented chronic history metabolic instability achieve acceptable metabolic control ( may include treatment use continuous insulin infusion pump ) without experience multiple episode hypoglycaemia , often unawareness Patients HbA1C ≥7 % ≤15 % calculated average last four consecutive HbA1C reading 8week baseline runin period . The difference high low four HbA1C read 1.0 % . Plasma Cpeptide &lt; 0.3 ng/ml follow glucagon stimulation test ( Scheen et al . 1996 ) If female , childbearing capability ( two year post menopausal undergone voluntary sterilisation consider enrolment ) Provision write informed consent . Patients require agree comply test visit specify protocol , ( partners/close contact ) also require consent longterm microbiological monitoring , integral part study Type 2 diabetes , define age onset &gt; 30 year and/or history treatment oral hypoglycaemic medication and/or insulin resistance ( define insulin dose requirement ≥1.2 U/kg/day ) An average HbA1C &lt; 7 % &gt; 15 % 8week baseline runin period Body mass index ( BMI ) ≥30 kg/m2 ≤9 kg/m2 Active infection , plasma Creactive protein ≥10 mg/L baseline Previous receipt organ , skin graft , tissue transplant human animal donor Treatment immunosuppressive medication another medical condition Previous history peritoneal disease abnormal finding baseline laparoscopy Previous abdominal surgery , exclude uncomplicated appendectomy , cholecystectomy caesarean section History pelvic inflammatory disease endometriosis Inability tolerate oral medication history significant malabsorption HIV antibody and/or risk factor HIV infection Positive hepatitis C antibody , positive hepatitis B surface antigen hepatitis B core antibody Kidney disease , define serum creatinine &gt; 130 μmol/L men &gt; 110 μmol/L woman and/or urinary albumin &gt; 500 mg/L and/or haematuria and/or active urinary sediment cast Diabetes microvascular complication define untreated , potentially visionthreatening proliferative preproliferative retinopathy maculopathy ; painful peripheral neuropathy ; autonomic neuropathy manifest postural hypotension ; gastroparesis diabetic enteropathy Diagnosis coeliac disease history gastrointestinal symptom include chronic recurrent diarrhoea , malabsorption , weight loss abdominal distension bloating exposure gluten product diet Serious comorbid condition likely affect participation study , include : 1 . Previous coronary heart disease manifest nonST elevation myocardial infarction ( NSTEMI ) , Qwave infarction unstable angina ; coronary artery bypass graft ( CABG ) ; percutaneous angioplasty 2 . Previous cerebrovascular disease manifest transient ischaemic attack ( TIAs ) stroke 3 . Peripheral vascular disease previous amputation 4 . History New York Heart Association ( NYHA ) class II , III IV congestive heart failure ( CHF ) and/or chronic atrial fibrillation 5 . Chronic obstructive pulmonary disease ( COPD ) asthma previous hospitalisation decompensation ; requirement mechanical ventilation stage ; longterm treatment oral corticosteroid 6 . Liver disease abnormal liver function test define serum bilirubin ≥20 µmol/L , and/or ALT ≥100 U/L , and/or GGT ≥100 U/L , and/or albumin &lt; 35 g/L 7 . Haematological disorder , include haemoglobin ≤110 g/L platelet count &lt; 80 x 109/L 8 . Peptic ulcer disease and/or history previous gastrointestinal bleeding 9 . Malignancy basal cell carcinoma 10 . History epilepsy 11 . Untreated hypothyroidism 12 . Known adrenal insufficiency History drug , substance alcohol addiction Any factor detect psychometric evaluation Visit 2 PreTx screen period may opinion Clinical Psychologist affect individual 's ability fully participate study Any condition , opinion Investigator , may interfere adherence study protocol , include dementia , mental illness , history nonadherence appointment treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>xenotransplantation</keyword>
	<keyword>type 1 diabetes</keyword>
	<keyword>porcine islet</keyword>
</DOC>